9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
The DOI matches its Crossref record; 104 of the 106 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc22-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc22-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While generally well tolerated, an increased risk of HHF was found with saxagliptin, which is re fl ected in its label, and there have been rare reports of arthralgia and hypersensitivity reactions with the DPP-4i class (16).”
In the citing paper
“Current treatment protocols propose considering weight impact when choosing diabetes treatment strategies, and GLP-1RAs have shown a notably positive therapeutic profile for overweight or obese individuals with T2DM. 78”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [78]
In the citing paper
“Currently, these guidelines recommend SGLT2is and GLP-1RAs as the preferred therapy among individuals with type 2 diabetes and comorbid ASCVD or HF, and SGLT2is among those with comorbid CKD [8, 9].”
In the citing paper
“The ADA/ EASD statement recommends that patients with T2D who have established ASCVD, CKD, or clinical heart failure be treated with an SGLT2i (or GLP-1 RA) with proven cardiovascular bene fi t as part of a glucose-lowering regimen independent of HbA1c, but with consideration of patient-speci fi c factors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [147]
In the citing paper
“Based on evidence from large cardiovascular outcomes trials, the latest professional society guidelines continue to recommend sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for patients with type 2 diabetes (T2D) and established cardiovascular disease (CVD).1,2”
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“Metformin is effective and safe, is inexpensive, and may reduce risk of cardiovascular events and death (45).”
BackgroundIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518 · cited 1×
“The ADA/EASD consensus report “Management of Hyperglycemia in Type 2 Diabetes, 2018” and the 2019 update (43,44) recommend a patient-centered approach to choosing appropriate pharmacologic treatment of blood glucose.”
BackgroundRiddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Chiang, J. L., Kirkman, M. S., Laffel, L. M. B., Peters, A. L., & Authors, O. B. O. T. T. 1. D. S. (2014) · Diabetes Care · doi:10.2337/dc14-1140 · Cited by 965
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699
Research works printed but not linked: 2
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
- Vaz, 2018, Effectiveness and safety of carbohydrate counting in the management of adult patients with type 1 diabetes mellitus: a systematic review and meta-analysis, Arch Endocrinol Metab, 62, 337
Cited by
Items 401–500 of 1,000
Value of radiomics-based two-dimensional ultrasound for diagnosing early diabetic nephropathy
Su, X., Shu, L., & Huang, Y. (2023) · Scientific Reports · doi:10.1038/s41598-023-47449-2 · Cited by 17
“S1–6 and Tables S4, 5.”
Chen, R., Aamir, A. H., Amin, M. F., Bunnag, P., Chan, S. P., Guo, L., Khamseh, M. E., Mohan, V., Nicodemus, N. A., Roberts, A., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01568-9 · Cited by 20
Yun, S., Hurren, K. M., Holleman, R. G., Klamerus, M. L., Tremblay, A. S., & Sussman, J. B. (2025) · BMC Family Practice · doi:10.1186/s12875-025-02709-0 · Cited by 19
Sun, M., Wang, X., Lu, Z., Yang, Y., Lv, S., Miao, M., Chen, W., Wu, S., & Zhang, J. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-004902 · Cited by 21
Changes in Type 2 Diabetes Medication Utilization and Costs in the United States, 2014–2019
Neilson, L. M., Munshi, K. D., Peasah, S. K., Huang, Y., Swart, E. C. S., Henderson, R. R., Manolis, C. H., & Good, C. B. (2021) · Medical Care · doi:10.1097/mlr.0000000000001597 · Cited by 17
Italian guidelines for the treatment of type 2 diabetes
Mannucci, E., Candido, R., Monache, L. D., Gallo, M., Giaccari, A., Masini, M. L., Mazzone, A., Medea, G., Pintaudi, B., Targher, G., et al. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.01.027 · Cited by 23
Diabetes in Kidney Transplantation
Cantarin, M. P. M. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.10.004 · Cited by 19
SGLT2 Inhibitor Use and Risk of Breast Cancer Among Adult Women with Type 2 Diabetes
Wang, F., HENDRYX, M. S., Liu, N., Bidulescu, A., Mitra, A. K., & Luo, J. (2023) · Drug Safety · doi:10.1007/s40264-023-01373-6 · Cited by 19
Song, Y., Ku, B. J., Cho, J., Jun, Y., Kim, B., & Nam, S. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.11.77 · Cited by 22
Kuchay, M. S., Choudhary, N. S., Mishra, S. K., & Misra, A. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.11.015 · Cited by 18
Husain, M., Consoli, A., De Remigis, A., Pettersson Meyer, A. S., Rasmussen, S., & Bain, S. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01489-6 · Cited by 16
Role of mitogen-activated protein kinase inhibitors in Alzheimer's disease: Rouge of brain kinases
Almasoudi, S. H., Al-Kuraishy, H. M., Al-Gareeb, A. I., Eliwa, D., Alexiou, A. T., Papadakis, M., & Batiha, G. E. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111296 · Cited by 16
“In 2022, American Diabetes Association (ADA) recommends that SGLT2Is as a first-line treatment in the management of T2D patients (American Diabetes Association Professional Practice, 2021).”
GLP-1 receptor agonists and the risk of fragility fractures in older adults with type 2 diabetes
Meron, M. K., Hornik‐Lurie, T., Twig, G., & Rotman‐Pikielny, P. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag056 · Cited by 18
Wang, T., Zhang, F., Wang, X., Li, X., Ling, H., Lv, D., Yin, X., & Lü, Q. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13134 · Cited by 39
Sun, Y., Mehmood, A., Giampieri, F., Battino, M. A., & Chen, X. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2023.2255666 · Cited by 17
“Table 2 summarizes the various classes of glucose-lowering medications and their mechanisms of actions (Draznin et al. 2022; Khan, Zahiruddin, and Ahmad 2020; Reddy and Tan 2020).”
Tong, K., Yin, S., Yu, Y., Yang, X., Hu, G., Zhang, F., & Liu, Z. (2023) · Medicine · doi:10.1097/md.0000000000035488 · Cited by 18
Li, Y., Gong, X., Găman, M., Hernández‐Wolters, B., Velu, P., & Li, Y. (2023) · European Journal of Clinical Investigation · doi:10.1111/eci.14125 · Cited by 21
Kim, J. S., Lee, G., Park, K., & Oh, S. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0421 · Cited by 19
“Metformin is the preferred initial pharmacologic agent for treating type 2 diabetes mellitus (T2DM), and other glucose-lowering agents can be considered according to comorbidities or patient-centered treatment factors [4,5].”
BackgroundThe cost of influence: How gifts to physicians shape prescriptions and drug costs
Newham, M., & Valente, M. (2024) · Journal of Health Economics · doi:10.1016/j.jhealeco.2024.102887 · Cited by 20
“The first line treatment is metformin (and comprehensive lifestyle modification) which is used for as long as the body tolerates it, thereafter different drugs are added to the treatment regimen (Draznin et al., 2022).”
BackgroundInfluentialMaking a Case for Whole Person Health
Herman, P. M., Pitcher, M. H., & Langevin, H. M. (2024) · Global Advances in Integrative Medicine and Health · doi:10.1177/27536130241293642 · Cited by 20
Tiwari, D., Loh, W. J., & Aw, T. C. (2025) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2025.101428 · Cited by 17
Moon, S. J., Yu, K., & Kim, M. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.04.005 · Cited by 17
Medically Complex Dental Implant Patients
Halpern, L. R., & Adams, D. R. (2020) · Dental Clinics of North America · doi:10.1016/j.cden.2020.08.001 · Cited by 16
Prescription Patterns of Novel Antihyperglycemic Medications
Ali, A. S., Khan, M., Ortega, D., Jaffery, S. H., Lamerato, L. E., & Budzynska, K. (2022) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2022.02.210360 · Cited by 16
Kim, C. H., Hwang, I.-C., Choi, H.-M., Ahn, C. H., Yoon, Y. E., & Cho, G.-Y. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.06.027 · Cited by 16
McCrimmon, R. J., CHENG, A. Y. Y., Galstyan, G. R., Djaballah, K., Li, X., Coudert, M., & Frías, J. P. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14844 · Cited by 17
Visolyi, G. Á., Domján, B. A., Svébis, M. M., Péterfi, A., Lovasz, B. D., Mészáros, S., Horváth, V. J., & Tabák, Á. G. (2023) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2023.03.002 · Cited by 18
Yang, Y., Min, K. W., Park, S., Kim, K., Yu, J. M., Hong, E., Cho, S., Won, K. C., Kim, Y. H., Oh, S., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15080 · Cited by 18
Dholariya, S. J., Dutta, S., Singh, R., Parchwani, D. N., Sonagra, A. D., & Kaliya, M. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2269854 · Cited by 18
“The selection of pharmacologic drugs should be guided by a patient-centered strategy, considering factors such as efficacy, safety, cost, accessibility, influence on weight, and coexisting renal and cardiovascular conditions [8–10].”
BackgroundPeralta, F. G., Martín, F. J. E. S., Torre, E. L. M., Mata‐Cases, M., García, J. C. F., Loiola, P. E., Lachica, L. Á., Pérez, J. A. F., Menéndez, S. A., Guisasola, F. Á., et al. (2018) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2018.11.010 · Cited by 20
Use of non-insulin diabetes medicines after insulin initiation: A retrospective cohort study
Xu, Y., Pilla, S. J., Alexander, G. C., & Murimi, I. B. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211820 · Cited by 16
Association of Patient-Provider Teach-Back Communication with Diabetic Outcomes: A Cohort Study
Hong, Y., Huo, J. S., Jo, A., Cardel, M. I., & Mainous, A. G. (2020) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2020.06.200217 · Cited by 18
The controversial role of glucose in the diabetic kidney
Fernandes, R. (2021) · Porto Biomedical Journal · doi:10.1097/j.pbj.0000000000000113 · Cited by 16
Liraglutide for the Treatment of Type 2 Diabetes and Safety in Diabetic Kidney Disease
Cherney, D. Z. I., & Tuttle, K. R. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01260120 · Cited by 18
Instituting a successful discharge plan for patients with type 2 diabetes: challenges and solutions
Demidowich, A. P., Batty, K., & Zilbermint, M. (2022) · Diabetes Spectrum · doi:10.2337/dsi22-0013 · Cited by 15
Abu-Nejim, H., & Becker, R. C. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01350-7 · Cited by 16
Arbel, R., Aboalhasan, E., Hammerman, A., & Azuri, J. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.03.040 · Cited by 16
Kaewbut, P., Kosachunhanun, N., Phrommintikul, A., Chinwong, D., Hall, J. J., & Chinwong, S. (2021) · Medicina · doi:10.3390/medicina58010063 · Cited by 17
Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes
Mosenzon, O., Schechter, M., & Leibowitz, G. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.04.005 · Cited by 16
Dubale, M., Gizaw, K., & Bosho, D. D. (2023) · Scientific Reports · doi:10.1038/s41598-023-42774-y · Cited by 17
“Therapeutic inertia (TI) was assessed based on data obtained from patients’ chart which includes information about the medication the patient was taking, its dose, frequency and duration and the obtained information was compared against the ADA guideline to look for the presence or absence of TI 4 .”
MethodGomes, D., Presume, J., Gonçalves, P. D. A., Almeida, M., Mendes, M., & Ferreira, J. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07547-3 · Cited by 18
“Despite this potential limitation of intensive glycemic control, the results of our meta-regression analyses support the new recommendation for the use of GLP-1 RAs as appropriate initial therapy for individuals with type 2 DM with or at high risk for ASCVD [34].”
Pan, S., Li, S., Jiang, S., Shin, J., Liu, G. G., Wu, H., & Lyu, B. (2024) · The Journals of Gerontology Series A · doi:10.1093/gerona/glae108 · Cited by 18
Tarar, Z. I., Farooq, U., Chaudhry, A., Gandhi, M. H., Alayli, A. E., Ayoub, M., Singh, B., Daglilar, E. S., & Thosani, N. C. (2025) · Diagnostics · doi:10.3390/diagnostics15060770 · Cited by 16
“These medications lead to weight loss, a lower risk of hypoglycemia, and cardiovascular and renal health benefits [3].”
Wu, Q., Liao, C., He, M., Li, C., Zou, F., Hu, L., Wei, Y., & Zhang, W. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13521 · Cited by 15
Casula, M., Catapano, A. L., & Magni, P. (2022) · Nutrients · doi:10.3390/nu14030606 · Cited by 17
“Pharmacologic Approaches to Glycemic Treatment [33,38]”
BackgroundJung, H. N., Cho, Y. K., Min, S. H., Kim, H. S., Kim, Y., Park, J., Lee, W. J., & Jung, C. H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.870722 · Cited by 17
Desai, R. J., Glynn, R. J., Everett, B. M., Schneeweiß, S., Wexler, D. J., Bessette, L. G., Déruaz‐Luyet, A., Vedin, O., Brodovicz, K. G., & Patorno, E. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.09.008 · Cited by 17
Falcetta, P., Nicolì, F., Citro, F., Ciccarone, A., Garofolo, M., Prato, S. D., & Bianchi, C. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01974-0 · Cited by 16
Taybani, Z. J., Bótyik, B., Gyimesi, A., Katkó, M., & Várkonyi, T. T. (2022) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.390 · Cited by 16
Lajara, R., Heller, C. G., Pantalone, K. M., Lew, E., Li, X., DEX, T. A., & Kilpatrick, C. R. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14974 · Cited by 16
Ohsugi, M., Eguchi, K., Mortensen, J. T., Yamamoto, Y., & Ueki, K. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110841 · Cited by 15
Effects of liraglutide on intrapancreatic fat deposition in patients with type 2 diabetes
Kuriyama, T., Ishibashi, C., Kozawa, J., Baden, M. Y., Horii, T., Niki, A., Ozawa, H., Hosokawa, Y., Fujita, Y., Sadahiro, K., et al. (2023) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2023.12.005 · Cited by 17
Hsieh, Y., Liao, Y., Li, C., Lin, J., Weng, C., Lin, C., Lo, C., Huang, K., Huang, J., Lin, C., et al. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3226 · Cited by 16
Wang, E., Patorno, E., Khosrow-Khavar, F., Crystal, S., & Dave, C. V. (2025) · Diabetologia · doi:10.1007/s00125-024-06321-2 · Cited by 14
“Currently, these guidelines recommend SGLT2is and GLP-1RAs as the preferred therapy among individuals with type 2 diabetes and comorbid ASCVD or HF, and SGLT2is among those with comorbid CKD [8, 9].”
Gao, Q., Zhang, W., Li, T., Yang, G., Zhu, W., Chen, N., & Hua-wei, J. (2021) · Medicine · doi:10.1097/md.0000000000027476 · Cited by 14
Albuminuria in diabetic patients: how to measure it?—a narrative review
Résimont, G., Cavalier, E., Radermecker, R. P., & Delanaye, P. (2022) · Journal of Laboratory and Precision Medicine · doi:10.21037/jlpm-21-58 · Cited by 19
Huynh, D. J., Renelus, B. D., & Jamorabo, D. S. (2023) · Annals of Gastroenterology · doi:10.20524/aog.2023.0814 · Cited by 19
Stan, S. I., Biciuşcă, V., Clenciu, D., Mitrea, A., Boldeanu, M. V., Durand, P., & Dănoiu, S. (2023) · Medicine and Pharmacy Reports · doi:10.15386/mpr-2629 · Cited by 18
Park, Y.-H., Sohn, M., Lee, S. Y., & Lim, S. K. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0128 · Cited by 17
Suzuki, Y., Kaneko, H., Nagasawa, H., Okada, A., Fujiu, K., Jo, T., Takeda, N., Morita, H., Nishiyama, A., Gohda, T., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15561 · Cited by 16
Deressa, H. D., Abuye, H., Adinew, A., Ali, M. K., Kebede, T., & Habte, B. M. (2024) · Global Health Research and Policy · doi:10.1186/s41256-024-00352-3 · Cited by 14
“Still, with early diagnosis and treatment, many of the harmful effects of the disease can be delayed or even avoided [2].”
BackgroundShanmuganathan, G., & Agrawal, D. K. (2024) · Archives of Internal Medicine Research · doi:10.26502/aimr.0169 · Cited by 14
“After lifestyle modification, the current first-line anti-hyperglycemic medication for patients with Type 2 Diabetes (T2DM) is metformin [49].”
BackgroundCannarella, R., Rubulotta, M., Cannarella, V., Vignera, S. L., & Calogero, A. E. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.06.010 · Cited by 16
Chan, M. K., Dimitriou, A., & Lam, S. (2020) · Cardiology in Review · doi:10.1097/crd.0000000000000351 · Cited by 14
National Asthma Education and Prevention Program 2020 Guidelines: What’s Important for Primary Care
Murphy, M. (2021) · The Journal of Family Practice · doi:10.12788/jfp.0219 · Cited by 16
Kataoka, Y., Nicholls, S. J., Andrews, J., Uno, K., Kapadia, S. R., Tuzcu, E. M., Nissen, S. E., & Puri, R. (2021) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-21-346 · Cited by 14
Glucagon-Like Peptide-1 Receptor Agonists—Use in Clinical Practice
Tricò, D., & Solini, A. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.04.002 · Cited by 15
Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?
Nicola, L. D., Cozzolino, M. G., Genovesi, S., Gesualdo, L., Grandaliano, G., & Pontremoli, R. (2022) · Journal of Nephrology · doi:10.1007/s40620-022-01336-7 · Cited by 17
Potential Therapeutic Targeting Neurotransmitter Receptors in Diabetes
Pan, X., Tao, S., & Tong, N. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.884549 · Cited by 15
Hanna, J. M., Nargesi, A. A., Essien, U. R., Sangha, V., Lin, Z., Krumholz, H. M., & Khera, R. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100370 · Cited by 15
Puangpet, T., Pongkunakorn, T., Chulkarat, N., Bunlangjit, C., Surawit, A., Pinsawas, B., Mongkolsucharitkul, P., & Mayurasakorn, K. (2022) · BMC Family Practice · doi:10.1186/s12875-022-01823-7 · Cited by 18
Grauslund, J., Pedersen, F. N., Andersen, N., Andresen, J., Bek, T., Dinesen, S., Hajari, J. N., Heegaard, S., Højlund, K., Laugesen, C. S., et al. (2022) · Acta Ophthalmologica · doi:10.1111/aos.15264 · Cited by 14
Does health information affect lifestyle behaviours? The impact of a diabetes diagnosis
Gaggero, A., Gil, J., Jiménez‐Rubio, D., & Zucchelli, E. (2022) · Social Science & Medicine · doi:10.1016/j.socscimed.2022.115420 · Cited by 17
Evaluating gliclazide for the treatment of type 2 diabetes mellitus
Tomlinson, B., Li, Y.-H., & Chan, P. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2141108 · Cited by 18
Kushner, P., Anderson, J. E., Simon, J., Boye, K. S., Ranta, K., Torcello-Gómez, A., & Levine, J. A. (2023) · Clinical Diabetes · doi:10.2337/cd22-0029 · Cited by 14
Arnold, S. V., de Lemos, J. A., Zheng, L., Rosenson, R. S., Ballantyne, C. M., Alam, S., Bhatt, D. L., Cannon, C. P., Kosiborod, M., & the GOULD Investigators (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15032 · Cited by 15
Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection
Yau, K., Odutayo, A., Dash, S., & Cherney, D. Z. I. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.07.007 · Cited by 22
Galindo, R. J., Uppal, T. S., McCoy, R. G., Umpierrez, G. E., & Ali, M. K. (2023) · Obesity · doi:10.1002/oby.23869 · Cited by 14
“For instance, the median average wholesale price for sulfonylureas (second generation) was reported to be 8 to 14 times lower than for exenatide, 10 to 18 times lower than for dula-glutide and semaglutide, and 12 to 22 times lower than for liraglutide [28].”
BackgroundBradley, C. L., McMillin, S. M., Hwang, A. Y., & Sherrill, C. H. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280221134127 · Cited by 13
Garofolo, M., Napoli, V., Lucchesi, D., Accogli, S., Mazzeo, M. L., Rossi, P., Neri, E., Prato, S. D., & Penno, G. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3585 · Cited by 16
Aroda, V. R., Frías, J. P., Ji, L., Niemoeller, E., Nguyên‐Pascal, M., Denkel, K., Espinasse, M., Guo, H., Baek, S. J., Choi, J., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15079 · Cited by 14
Maurer, J. A., Zhao, X., Irmler, M., Gudiksen, A., Pilmark, N. S., Li, Q., Goj, T., Beckers, J., de Angelis, M. H., Birkenfeld, A. L., et al. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00186.2023 · Cited by 15
“Since the approval of metformin by the FDA in 1994, the oral antidiabetic drug has become essential in the treatment of type 2 diabetes as fi rst-line therapy and is daily taken by over 150 million people worldwide (1).”
BackgroundAssociation between unstable diabetes mellitus and risk of pancreatic cancer
Ali, S., Coory, M. D., Donovan, P. J., Na, R., Pandeya, N., Pearson, S., Spilsbury, K., Stewart, L. M., Thompson, B. S., Tuesley, K., et al. (2023) · Pancreatology · doi:10.1016/j.pan.2023.11.009 · Cited by 14
Pérez, M. I. R., Ojeda, L. F., García‐Luna, P. P., Rocamora, J. A. I., Olveira, G., Lacalle-Remigio, J. R., Irigoyen, C. A., Continente, A. J. C., Martín, C. C., Soto, M. L. F., et al. (2023) · Nutrients · doi:10.3390/nu15234976 · Cited by 15
“Metformin is a safe and effective drug that can reduce the risk of cardiovascular events [22].”
BackgroundPakkam, M., Orscelik, A., Musmar, B., Tolba, H., Ghozy, S. A., Şenol, Y. C., Bilgin, C., Nayak, S. S., Kadirvel, R., Brinjikji, W., et al. (2024) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2024.107716 · Cited by 13
O’Hara, D. V., Janse, R. J., Fu, E. L., Jardine, M., & Carrero, J. J. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111745 · Cited by 15
Kohlman-Trigoboff, D., Rich, K. A., Foley, A., Fitzgerald, K. R., Arizmendi, D., Robinson, C., Brown, R., & Treat‐Jacobson, D. (2020) · Journal of Vascular Nursing · doi:10.1016/j.jvn.2020.01.004 · Cited by 17
Pharmacological therapies to address obesity in type 1 diabetes
Casu, A., Bilal, A., & Pratley, R. E. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000555 · Cited by 16
Koufakis, T., Liberopoulos, E. N., & Kotsa, K. (2022) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-022-00527-8 · Cited by 13
Posttranslational modifications in diabetes: Mechanisms and functions
Hu, A., Zou, H., Chen, B., & Zhong, J. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09740-x · Cited by 14
“, exogenous insulin is still the most important and widely prescribed medication for T1D [85].”
BackgroundPedrosa, A. R., Martins, D. C., Rizzo, M., & Silva‐Nunes, J. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108391 · Cited by 13
Cardoso, H., Bello, C., Andrade, L., do Rosário, F. S., Louro, J., Nogueira, C., Rodrigues, E., Vieira, N., & Carqueja, T. (2023) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2022.04.011 · Cited by 14
Ares, J., Lambert, C., Fernández‐Sanjurjo, M., Morales-Sánchez, P., Pujante, P., Pinto-Hernández, P., Iglesias‐Gutiérrez, E., Torre, E. L. M., & Delgado, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021152 · Cited by 13
Htoo, P. T., Paik, J. M., Alt, E. M., Kim, D. H., Wexler, D. J., Kim, S. C., & Patorno, E. (2023) · The Journals of Gerontology Series A · doi:10.1093/gerona/glad075 · Cited by 14
Liu, Y., Li, W., Chen, Y., & Wang, X. (2023) · Endocrine · doi:10.1007/s12020-023-03499-0 · Cited by 14
Chang, H., Chen, Y., Kuo, T., Lin, Y., Chien, K., Chang, H., Hung, C., & Chung, F. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032397 · Cited by 15
“6,8 Furthermore, clinical trials have demonstrated that SGLT2 inhibitors reduce the risk of renal failure among patients with type 2 diabetes and CKD. 2,4,5 12 Although these studies signified the compelling findings of the primary prevention role for SGLT2 inhibitors, most studies compared the…”
Diabetes health management strategy based on internet plus graded diagnosis and treatment strategy
Liang, G., Jiang, H., Huang, C., Que, X., Tang, J., Lu, J., & Gao, J. (2020) · Annals of Palliative Medicine · doi:10.21037/apm-20-1996 · Cited by 15
Nashawi, M., Sheikh, O., Battisha, A., Ghali, A. N., & CHILTON, R. J. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-10046-w · Cited by 13
Mantovani, A., & Targher, G. (2021) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-2021-13 · Cited by 15
Tirzepatide: Clinical review of the twincretin injectable
Krauss, Z., Hintz, A., & Fisk, R. (2023) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxad080 · Cited by 12
Metadata
- Authors
- American Diabetes Association Professional Practice Committee
- Corresponding author
- American Diabetes Association Professional Practice Committee
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2021-12-16
- Volume
- 45
- Issue
- Supplement_1
- Pages
- S125-S143
- ISSN
- 0149-5992 (ISSN-L)
- OpenAlex
- W4200161106
- Cited by
- 1,555
- References
- 106
- Citations by year
- 2026: 42 · 2025: 132 · 2024: 219 · 2023: 393 · 2022: 403 · 2021: 153
- FWCI
- 44.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic control, pharmacotherapy, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.